Regeneron Pharmaceuticals' Other Operating Expenses rose 225.00% to $10.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.0 billion, marking a year-over-year increase of 2804.01%. This contributed to the annual value of -$53.4 million for FY2024, which is 2642.86% down from last year.
Regeneron Pharmaceuticals' Other Operating Expenses amounted to -$53.4 million in FY2024, which was down 2,642.86% from $2.1 million recorded in FY2023.
Regeneron Pharmaceuticals' 5-year Other Operating Expenses high stood at $280.4 million for FY2020, and its period low was -$53.4 million during FY2024.
Over the past 3 years, Regeneron Pharmaceuticals' median Other Operating Expenses value was $2.1 million (recorded in 2023), while the average stood at $12.9 million.
As far as peak fluctuations go, Regeneron Pharmaceuticals' Other Operating Expenses soared by 97.15% in 2022, and later crashed by 2,642.86% in 2024.
Regeneron Pharmaceuticals' Other Operating Expenses (Yearly) stood at $280.4 million in 2020, then plummeted by 83.74% to $45.6 million in 2021, then surged by 97.15% to $89.9 million in 2022, then crashed by 97.66% to $2.1 million in 2023, then crashed by 2,642.86% to -$53.4 million in 2024.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value